Geode Capital Management
ABCL icon

Geode Capital Management’s AbCellera Biologics ABCL Stock Holding History

Geode Capital Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.48M Buy
315,721
+6,330
+2% +$30.9K ﹤0.01% 3145
2026
Q1 		$1.08M Sell
309,391
-4,076
-1% -$14.7K ﹤0.01% 3341
2025
Q4 		$1.07M Sell
313,467
-15,756
-5% -$70.3K ﹤0.01% 3358
2025
Q3 		$1.66M Sell
329,223
-33,965
-9% -$150K ﹤0.01% 3244
2025
Q2 		$1.25M Buy
363,188
+12,301
+4% +$30.6K ﹤0.01% 3265
2025
Q1 		$782K Buy
350,887
+237,114
+208% +$680K ﹤0.01% 3391
2024
Q4 		$333K Buy
113,773
+120
+0.1% +$334 ﹤0.01% 3728
2024
Q3 		$295K Sell
113,653
-201,213
-64% -$558K ﹤0.01% 3773
2024
Q2 		$932K Buy
314,866
+57,500
+22% +$218K ﹤0.01% 3334
2024
Q1 		$1.17M Buy
257,366
+1,222
+0.5% +$6.24K ﹤0.01% 3308
2023
Q4 		$1.46M Buy
256,144
+846
+0.3% +$3.92K ﹤0.01% 3205
2023
Q3 		$1.17M Buy
255,298
+3,624
+1% +$22K ﹤0.01% 3256
2023
Q2 		$1.63M Sell
251,674
-1,923,874
-88% -$13.1M ﹤0.01% 3177
2023
Q1 		$16.4M Buy
2,175,548
+108,035
+5% +$981K ﹤0.01% 1932
2022
Q4 		$20.9M Buy
2,067,513
+82,316
+4% +$951K ﹤0.01% 1742
2022
Q3 		$19.6M Buy
1,985,197
+55,399
+3% +$608K ﹤0.01% 1750
2022
Q2 		$20.6M Buy
1,929,798
+1,727,090
+852% +$14.6M ﹤0.01% 1755
2022
Q1 		$1.98M Buy
202,708
+840
+0.4% +$7.95K ﹤0.01% 3264
2021
Q4 		$2.89M Buy
201,868
+170,204
+538% +$2.58M ﹤0.01% 3189
2021
Q3 		$634K Sell
31,664
-167,074
-84% -$2.95M ﹤0.01% 3917
2021
Q2 		$4.37M Buy
198,738
+3,201
+2% +$88.3K ﹤0.01% 2985
2021
Q1 		$6.64M Buy
195,537
+5,431
+3% +$216K ﹤0.01% 2637
2020
Q4 		$7.65M Buy
+190,106
New +$8.69M ﹤0.01% 2337

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Geode Capital Management's ABCL Position: Q2 2026 in Review

Geode Capital Management increased its AbCellera Biologics (ABCL) stake by 2% in Q2 2026, buying an estimated $30.9K and bringing the position to 315,721 shares worth $2.48M. The position accounts for ﹤0.01% of the portfolio, ranked #3145.

Geode Capital Management first reported a position in ABCL in Q4 2020 and has held it in 23 quarters since. The position peaked at $20.9M in Q4 2022. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Geode Capital Management held 315,721 shares of AbCellera Biologics worth $2.48M as of Q2 2026.
  • Geode Capital Management bought 6,330 AbCellera Biologics shares in Q2 2026, an estimated $30.9K.
  • AbCellera Biologics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3145 holding.
  • Geode Capital Management first reported a position in AbCellera Biologics in Q4 2020 and has held it in 23 quarters since.
  • Geode Capital Management's AbCellera Biologics position peaked at $20.9M in Q4 2022.
  • 151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.